Ownership Capital B.V. Sells 438,917 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Ownership Capital B.V. lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 15.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,353,348 shares of the medical research company's stock after selling 438,917 shares during the quarter. Edwards Lifesciences accounts for about 7.8% of Ownership Capital B.V.'s holdings, making the stock its 2nd biggest position. Ownership Capital B.V. owned approximately 0.40% of Edwards Lifesciences worth $170,571,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in EW. Allspring Global Investments Holdings LLC boosted its stake in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after acquiring an additional 145 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $49,038,000. Dynamic Advisor Solutions LLC boosted its stake in shares of Edwards Lifesciences by 2.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after acquiring an additional 370 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Edwards Lifesciences by 13.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after buying an additional 9,188 shares in the last quarter. Finally, Simplify Asset Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $5,979,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.9%

Edwards Lifesciences stock traded down $0.73 during trading on Friday, reaching $78.07. 3,780,176 shares of the company's stock were exchanged, compared to its average volume of 5,256,833. The company's 50-day moving average is $76.25 and its two-hundred day moving average is $73.36. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. Edwards Lifesciences Corporation has a 52-week low of $58.93 and a 52-week high of $92.88. The firm has a market cap of $45.79 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 3.96 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The firm had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same period in the prior year, the company earned $0.66 EPS. The firm's revenue was up 6.2% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the transaction, the vice president directly owned 33,496 shares of the company's stock, valued at $2,514,879.68. This represents a 4.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the completion of the transaction, the vice president directly owned 47,206 shares of the company's stock, valued at approximately $3,295,450.86. The trade was a 16.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,348 shares of company stock worth $2,977,683 over the last quarter. Company insiders own 1.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on EW shares. Piper Sandler upped their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Evercore ISI upped their target price on Edwards Lifesciences from $73.00 to $77.00 and gave the company an "in-line" rating in a research note on Tuesday. Citigroup reaffirmed a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Finally, Truist Financial reduced their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $80.40.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.